Key result
Discontinuation of novel oral anticoagulants within 90 days after thoracoscopic left atrial appendage resection led to thromboembolic complications in 4 of 11 (36.4%) non-compliant patients.
Why the study?
The study was conducted to examine patterns in the development of thromboembolic complications after surgeries involving left atrial appendage resection.
Does early discontinuation of NOACs increase thromboembolic complications in patients with atrial fibrillation after thoracoscopic left atrial appendage resection?
Cohort (n=114)
Does early discontinuation of NOACs increase thromboembolic complications in patients with atrial fibrillation after thoracoscopic left atrial appendage resection?
Anticoagulant therapy should be continued for at least 90 days after thoracoscopic LAA resection and radiofrequency ablation due to a high risk of thromboembolic complications upon early discontinuation.
Early NOAC discontinuation was associated with thromboembolic events post-thoracoscopic LAA resection; leaves open optimal duration in randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vachev et al. (2021) conducted a cohort in Atrial fibrillation (n=114). Novel oral anticoagulants (NOACs) vs. Discontinuation of NOACs within 90 days was evaluated on Thromboembolic complications. Discontinuation of novel oral anticoagulants within 90 days after thoracoscopic left atrial appendage resection led to thromboembolic complications in 4 of 11 (36.4%) non-compliant patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: